glp-1 medications available new zealand Pharma pauses candidate: Competition is too fierce Obesity drug from Zealand shows

Patel DP, et al

May 11, 2025

Beyond these core benefits, these treatments actively support long-term wellness by reducing the risk of major cardiovascular eventssuch as heart attack and strokewhile simultaneously protecting kidney function, improving liver health, and alleviating obesity-related conditions like obstructive sleep apnea

4 In a second meta-analysis study from 2019, which collected data from large-scale cardiovascular outcome trials, found that of the 56,004 patients on a GLP-1 agonist with type 2 diabetes, 180 experienced acute pancreatitis, and 108 cases of pancreatic cancer were reported

None of these are safe to inject